

FERTIPROT - A NOVEL TOPICAL OR EX-VIVO FORMULATION OF FOR INCREASED FERTILIZATION, FERTILITY EFFICACY AND INCREASING TAKE-HOME BABY RATE.

Shemesh, Ronen

Submission Group SARG submissions

Abstract Body

A Novel Topical or Ex-vivo Formulation for increased fertilization, Fertility efficacy and Increasing Take-Home Baby Rate.

One in every seven couples suffer from impaired fertility. Recent publications indicate that the fertility potential of males is declining globally due to a significant reduction in sperm counts (up to 80% of sperm donors were designated 'subfertile'), but also due to poor sperm parameters, like motility, endurance etc. **Fertiprot's technology and device will increase "Take Home Baby Rate" dramatically**, and enhance probability of success both in spontaneous fertilization, and IntraUterine Insemination (IUI), while reducing the need for IVF, in 20%-30% of subfertile and infertile couples. Thus reducing the need for invasive, unpleasant and costly procedures involved in the IVF process. This solution is aimed mostly at male factor and unexplained subfertile couples/individuals.

FertiProt bases its innovative technology on evolutionary, chemical and biological properties of the fertilization process and by enhancing fertilization potency through a non-invasive technology and drug-device integration, for enhancing sperm properties and potential for fertilization using addition of formulated chemical active compounds (APIs). We have a list of candidates, some of which are approved for other (non-fertility related) indications that might be available for development pending a short screening. The unique and novel formulation and technology will improve efficacy and safety and reduce (by 20%-30%) the need for invasive and hormonal based treatments such as IVF, with a natural, easy to use and risk free process that will increase the chances of conception for couples with fertility impairment, either by enhancing efficiency of artificial insemination or through increasing conception chances for natural intercourse. The novel technology will also help with family planning for normal couples as well. The company will use proprietary methods to increase the chances of conceiving through natural means and artificial insemination both for normal and infertile couples.

The company sees the market of fertility impaired couples as a major unmet need as well as a field where innovation and originality might discover niches presently neglected by the biotech/pharmaceutical industry. The product will be an advanced repositioned NCE or a similar molecule, scientifically proven to improve sperm motility and endurance in-vitro.

Abstract image

